Tag Archives: national science agency

Blood test for Alzheimer’s

Scientists are closing in on a long-sought goal: A blood test to screen people for Alzheimer’s disease.

An experimental test did a good job of indicating how much of the tell tale Alzheimer’s plaque lurks in people’s brains, according to Australian researchers.

If the test proves accurate in larger studies, it could offer a way to check people having memory problems to see who needs more definitive testing for the disease.

Many blood tests are being developed and a few are used in research settings now, but only the Australian one has been validated against brain scans and other accepted diagnostic tests with good accuracy in large groups of people, said Maria Carrillo, senior director of medical and scientific relations for the Alzheimer’s Association.

The results, reported at the Alzheimer’s Association International Conference in France, ‘give us hope that we may be able to use a blood test in the near future,’ although that doesn’t mean next year, she said.

Alzheimer’s disease

Alzheimer’s disease

More than 5.4 million Americans and 35 million people worldwide have Alzheimer’s, the most common form of dementia. It has no cure and drugs only temporarily ease symptoms. Finding it early allows patients and their families to prepare, and ruling it out could lead to diagnosing a more treatable cause of symptoms, such as sleep problems.

Brain scans can show signs of Alzheimer’s – sticky clumps of a protein called beta amyloid – a decade or more before it causes memory and thinking problems, but scans are too expensive and impractical for routine use. Doctors and patients need simple ways to screen people for the disease.

Samantha Burnham and others at Australia’s national science agency, CSIRO, working with several universities, used a long-running study of more than 1,100 people – some healthy, some impaired – to develop the blood test.

They started with blood samples from 273 study participants and identified nine hormones and proteins that seemed most predictive of amyloid levels in the brain. A cutoff level was set for what was considered high.

‘The belief is that people above that point will go on to get Alzheimer’s disease, and the lag is about 8 to 10 years,’ Burnham explained.


When researchers used the nine-marker blood test on these same participants, they found that it separated healthy people from those with mild cognitive impairment or Alzheimer’s as verified by their brain scans.

The test correctly identified 83 percent of people with high amyloid levels and correctly ruled out 85 percent of people without this condition.

‘That’s pretty high,’ the Alzheimer’s Association’s Carrillo said of the test’s accuracy.

More importantly, she said, the Australian researchers validated the test’s accuracy in two additional groups: the other 817 folks in the Australian study and 74 people in a big U.S.-led study aimed at finding novel Alzheimer’s disease biomarkers.

The test performed well in those situations, too, Burnham said.

CSIRO has patented the test and is talking with major companies about making it commercially available.

‘It sounds like the Australians do have good clinical data’ and that the markers they are testing for track with cases of the disease, said Creighton Phelps, a neuroscientist with the U.S. National Institute on Aging.

The next step is wider validation work and ensuring it can be standardised to give reliable results regardless of what lab or doctor would use it, he said.

Eye test for Alzheimer’s

Scientists in Australia are reporting encouraging early results from a simple eye test they hope will give a noninvasive way to detect signs of Alzheimer’s disease.

Although it has been tried on just a small number of people and more research is needed, the experimental test has a solid basis: Alzheimer’s is known to cause changes in the eyes, not just the brain. Other scientists in the United States also are working on an eye test for detecting the disease.

A separate study found that falls might be an early warning sign of Alzheimer’s.

People who seemed to have healthy minds but who were discovered to have hidden plaques clogging their brains were five times more likely to fall during the study than those without these brain deposits, which are a hallmark of Alzheimer’s.

Both studies were discussed Sunday at the Alzheimer’s Association International Conference in France.

More than 5.4 million Americans and 35 million people worldwide have Alzheimer’s, the most common form of dementia. It has no cure and drugs only temporarily ease symptoms, so finding it early mostly helps patients and their families prepare and arrange care.

Brain scans can find evidence of Alzheimer’s a decade or more before it causes memory and thinking problems, but they’re too expensive and impractical for routine use. A simple eye test and warning signs like falls could be a big help.

The eye study involved photographing blood vessels in the retina, the nerve layer lining the back of the eyes. Most eye doctors have the cameras used for this, but it takes a special computer program to measure blood vessels for the experimental test doctors are using in the Alzheimer’s research, said the study’s leader, Shaun Frost of Australia’s national science agency, CSIRO.

Alzheimer's

Alzheimer's

Researchers compared retinal photos of 110 healthy people, 13 people with Alzheimer’s and 13 others with mild cognitive impairment, or “pre-Alzheimer’s,” who were taking part in a larger study on aging. The widths of certain blood vessels in those with Alzheimer’s were different from vessels in the others and the amount of difference matched the amount of plaque seen on brain scans.

More study is planned on larger groups to see how accurate the test might be, Frost said.

Earlier work by Dr. Lee Goldstein of Boston University showed that amyloid, the protein that makes up Alzheimer’s brain plaque, can be measured in the lens of the eyes of some people with the disease, particularly Down syndrome patients who often are prone to Alzheimer’s.

A company he holds stock in, Neuroptix, is testing a laser eye scanner to measure amyloid in the eyes. Goldstein praised the work by the Australian scientists.

“It’s a small study” but “suggestive and encouraging,” he said. “My hat’s off to them for looking outside the brain for other areas where we might see other evidence of this disease.”

Eye doctors often are the first to see patients with signs of Alzheimer’s, which can start with vision changes, not just the memory problems the disease is most known for, said Dr. Ronald Petersen, a Mayo Clinic dementia expert with no role in the new studies.

Other signs could be balance and gait problems, which may show up before mental changes do. Susan Stark of Washington University in St. Louis led the first study tying falls to a risk of developing Alzheimer’s disease before mental changes show up.


It involved 125 people, average age 74, who had normal cognition and were taking part in a federally funded study of aging. They kept journals on how often they fell, and had brain scans and spinal taps to look for various substances that can signal Alzheimer’s disease.

In six months, 48 fell at least once. The risk of falling was nearly three times greater for each unit of increase in the sticky plaque that scans revealed in their brains.

“Falls are tricky” because they can be medication-related or due to dizziness from high blood pressure, a blood vessel problem or other diseases like Parkinson’s, said Creighton Phelps, a neuroscientist at the National Institute on Aging.

Falls also can cause head injury or brain trauma that leads to cognitive problems, said Laurie Ryan, who oversees some of the institute’s research grants but had no role in the study. Older people who hit their heads and suffer a small tear or bleeding in the brain might seem fine but develop symptoms a month later, she said.

The bottom line: “If you see somebody who’s having falls for no particular reason,” the person should be evaluated for dementia, said William Thies, the Alzheimer’s Association’s scientific director.